Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer
NCT05184400 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2022-01-11
Summary
No validated biomarkers exist that can identify patients with biliary tract cancer at an early stage or predict treatment outcomes. The objective of the present study is to find diagnostic, prognostic and predictive biomarkers.
Conditions
- Biliary Tract Cancer
- Cholangiocarcinoma
- Gallbladder Cancer
Sponsors & Collaborators
-
Herlev and Gentofte Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-01-01
- Primary Completion
- 2030-12-31
- Completion
- 2030-12-31
Countries
- Denmark
Study Locations
More Related Trials
-
Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
NCT06648057 ·Status: RECRUITING
-
Molecular Profiling of Advanced Biliary Tract Cancers
NCT03419247 ·Status: WITHDRAWN ·Phase: NA
-
The Role of ctDNA and PBMC in Treatment of Biliary Tract Cancer
NCT02809898 ·Status: UNKNOWN
-
Protein Biomarker in Hepatocellular Carcinoma
NCT00465842 ·Status: TERMINATED
-
MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer
NCT02773459 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215)
NCT01521780 ·Status: TERMINATED ·Phase: PHASE1
-
Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing
NCT05520788 ·Status: RECRUITING
-
Precision Medicine for Combined Hepatocellular-Cholangiocarcinoma
NCT06146127 ·Status: RECRUITING
-
A Population-Based Case-Control Study of Biliary Tract Cancers in Shanghai, China
NCT00339560 ·Status: COMPLETED
-
NGS as the First-line Treatment in Advanced Biliary Tract Cancer
NCT04172402 ·Status: COMPLETED ·Phase: PHASE2
-
On-treatment Surveillance of Tumor Evolution and Response to Systemic Treatment in Bile Duct and Liver Cancer
NCT06877637 ·Status: RECRUITING
-
Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards
NCT05681949 ·Status: UNKNOWN ·Phase: NA
-
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
NCT01425879 ·Status: COMPLETED ·Phase: PHASE2
-
Circulating Tumor DNA Guided Adjuvant Chemotherapy for Biliary Tract Carcinoma
NCT06171321 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
The Detection of Circulating Tumor Cells (CTCs) in Patients With Liver Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment
NCT02416635 ·Status: COMPLETED
-
Artificial Intelligence and Hepatocellular Carcinoma
NCT05637788 ·Status: ACTIVE_NOT_RECRUITING
-
Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTC
NCT06699459 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Circulating Tumor Cells and Tumor DNA in HCC and NET
NCT02973204 ·Status: COMPLETED
-
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
NCT06777316 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Chromosomal Abnormalities as a Predictor of Staging and Prognosis in Patients With Liver Cancer
NCT05371873 ·Status: UNKNOWN
-
Primary Hepatobiliary Cancer Cohort of Central China
NCT05520801 ·Status: RECRUITING
-
Evaluation of Hepatic Arterial Infusion of Cisplatin and 5-FU in Biomarker Stratified HCC
NCT02967887 ·Status: UNKNOWN ·Phase: PHASE2
-
Prospective Evaluation of 68Ga-FAPI PET in Biliary Cancers
NCT07337850 ·Status: RECRUITING
-
Gemcitabine Plus High-Dose 5-Fu/Leucovorin in the Treatment of Advanced or Metastatic Carcinoma of the Biliary Tract
NCT00201305 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers
NCT04466891 ·Status: COMPLETED ·Phase: PHASE2